FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 126 filers reported holding FATE THERAPEUTICS INC in Q1 2019. The put-call ratio across all filers is 0.88 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $40,000 | -32.2% | 680 | 0.0% | 0.01% | -28.6% |
| Q2 2021 | $59,000 | -6.3% | 680 | -10.9% | 0.01% | 0.0% |
| Q1 2021 | $63,000 | -22.2% | 763 | -14.7% | 0.01% | -22.2% |
| Q4 2020 | $81,000 | -36.2% | 894 | -84.3% | 0.01% | -52.6% |
| Q1 2020 | $127,000 | +9.5% | 5,700 | -4.2% | 0.02% | +35.7% |
| Q4 2019 | $116,000 | -48.7% | 5,950 | -59.0% | 0.01% | -41.7% |
| Q3 2019 | $226,000 | -23.4% | 14,525 | -0.1% | 0.02% | -22.6% |
| Q2 2019 | $295,000 | +16.1% | 14,535 | +0.5% | 0.03% | -48.3% |
| Q1 2019 | $254,000 | +30.9% | 14,462 | -4.4% | 0.06% | +27.7% |
| Q4 2018 | $194,000 | -31.7% | 15,127 | -13.2% | 0.05% | -16.1% |
| Q3 2018 | $284,000 | +94.5% | 17,434 | +35.2% | 0.06% | +93.1% |
| Q2 2018 | $146,000 | +147.5% | 12,899 | +113.7% | 0.03% | +141.7% |
| Q1 2018 | $59,000 | – | 6,036 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 569,889 | $46,987,000 | 60.92% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,379,064 | $278,604,000 | 36.08% |
| Darwin Global Management, Ltd. | 1,370,133 | $112,967,000 | 22.12% |
| Redmile Group, LLC | 12,957,222 | $1,068,323,000 | 15.05% |
| Copernicus Capital Management, LLC | 8,000 | $660,000 | 10.66% |
| Casdin Capital, LLC | 3,400,000 | $280,330,000 | 8.35% |
| Grosvenor Holdings, L.L.C. | 1,123,576 | $92,639,000 | 6.81% |
| DAFNA Capital Management LLC | 314,360 | $25,919,000 | 6.15% |
| Ally Bridge Group (NY) LLC | 270,000 | $22,262,000 | 4.27% |
| Ghost Tree Capital, LLC | 185,000 | $15,253,000 | 3.58% |